Item 7.01. Regulation FD Disclosure.


On April 2, 2023, Gelesis Holdings, Inc. (the "Company") received a non-binding
indication of interest from PureTech Health LLC ("PureTech") (Nasdaq: PRTC, LSE:
PRTC) to acquire all of the outstanding capital stock of the Company for $0.21
per share, payable in shares of PureTech. The terms of any potential agreement
between the Company and PureTech would be contingent on certain conditions,
including approval by PureTech's board of directors and a special committee of
the Company's board of directors and negotiation of definitive transaction
documents. The indication of interest also contains a non-binding offer to
provide $5 million of senior secured financing to fund day-to-day operations of
the Company, the terms of which are to be negotiated and determined.
The Company also notes that it is currently evaluating various strategic
alternatives. The Company's board of directors will carefully evaluate
PureTech's indication of interest within the context of its ongoing review of
various strategic alternatives and in consultation with its financial and legal
advisors.
No assurance can be given that a definitive agreement with respect to PureTech's
indication of interest will be executed or that any other potential transaction
will be consummated. The Company does not undertake any obligation to provide
any updates with respect to any transaction, except as required under applicable
law.
The information in this Item 7.01 is being furnished and shall not be deemed
"filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the "Exchange Act"), or otherwise subject to liabilities under that
section, and shall not be deemed to be incorporated by reference into the
filings of the Company under the Securities Act of 1933, as amended, or the
Exchange Act, regardless of any general incorporation language in any such
filing. This Current Report on Form 8-K will not be deemed an admission as to
the materiality of any of the information contained in this Item 7.01.

Cautionary Note Regarding Forward-Looking Statements Certain statements, estimates, targets and projections in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws. The words "anticipate," "believe," continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "strive," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, statements regarding the Company's or its management team's expectations, hopes, beliefs, intentions or strategies regarding the future, including those relating to the Company's expected operating and financial performance and market opportunities. In addition, any statements that refer to guidance, projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. The Company gives no assurance that any expectations set forth in this press release will be achieved. Various risks and uncertainties (some of which are beyond the Company's control) or other factors could cause actual future results, performance or events to differ materially from those described herein. Some of these potential risks and uncertainties include, but are not limited to, uncertainty as to the pricing, timing or terms of any transaction with PureTech or any other alternative transactions and other factors which can be found in section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and in other filings that the Company makes with the Securities and Exchange Commission. These filings address important risks and uncertainties that could cause actual results and events to differ materially from those contained in the forward-looking statements.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses